BW

IRF-3 (phospho-S385) polyclonal Antibody | BS4609

(No reviews yet) Write a Review
SKU:
BW-BS4609
Availability:
Usually ships in 5 working days
NULL382.00 - NULL584.00

Description

IRF-3 (phospho-S385) polyclonal Antibody | BS4609 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: IRF-3 can inhibit cell growth and plays a critical role in controlling the expression of genes in the innate immune response. In unstimulated cells, IRF-3 is present in the cytoplasm. Viral infection results in phosphorylation of IRF-3 and leads to its translocation to the nucleus where it activates promoters containing IRF-3-binding sites. Phosphorylation of IRF-3 occurs at a cluster of C-terminal Ser and Thr residues (between 385 and 405), leading to its association with the p300/CBP coactivator protein that promotes DNA binding and transcriptional activity. During infection, IRF-3 is likely activated through a pathway that includes activation of Toll-like receptors and a kinase complex that includes IKKε and TBK1. IRF-3 is phosphorylated at Ser396 following viral infection, expression of viral nucleocapsid, and double-stranded RNA treatment. These events likely play a role in activation of IRF-3.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: p-IRF-3 (S385) polyclonal Antibody detects endogenous levels of IRF-3 protein only when phosphorylated at Ser385

Molecular Weight: ~ 47, 55 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: IRF3, IRF-3, IRF3, Interferon regulatory factor 3

Immunogen: Synthetic phosphopeptide derived from human IRF-3 around the phosphorylation site of Serine 385.

Conjugate: N/A

Modification: N/A

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: N/A

View AllClose